SMILE (Steroid + MTX + Ifosfamide + L-asparaginase + Etoposide), 2-4 cycles

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	None declared

ID	`REG-SMILE`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-BCELL-2025`

Notes

STUB. Yamaguchi 2008 — Asian standard. Alternative — P-GEMOX (cisplatin + gemcitabine + oxaliplatin) for centers without asparaginase. For localized stage I/II — concurrent CRT with RT 50 Gy + 2-3 cycles modified-DeVIC.

Used By

Indication

IND-NK-T-NASAL-1L-SMILE - IND-NK-T-NASAL-1L-SMILE